Healthcare / Drug Manufacturers - Specialty & GenericBSE
$7.89
-0.70 (-8.15%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-57.0M · quality 69.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$486M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-10.2%
↓Gross Margin
14.6%
↓Debt/Equity
0.16
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+194.5%
FCF CAGR
—
FCF margin
-73.7%
FCF / Net income
1.60x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $100.7M · net income $-46.5M · FCF $-74.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $100.7M | $100.7M | $102.9M | $10.0M | $3.9M |
| Net Income | $-46.5M | $-46.5M | $-45.1M | $-56.6M | $-8.9M |
| EBITDA | $-36.2M | $-36.2M | $-32.2M | $-39.5M | $-11.0M |
| EPS | -0.79 | -0.79 | -1.03 | -1.54 | -0.24 |
| Gross Margin | 14.6% | 14.6% | 11.1% | -195.4% | -0.7% |
| Operating Margin | -45.9% | -45.9% | -37.9% | -386.8% | -462.9% |
| Net Margin | -46.1% | -46.1% | -43.9% | -564.1% | -225.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.16 | 0.16 | 0.20 | 0.27 | 0.35 |
| Cash Flow | |||||
| Free Cash Flow | $-74.2M | $-74.2M | $-57.0M | $-29.8M | $-10.1M |
| Returns | |||||
| ROE | -10.2% | -10.2% | -11.2% | -15.4% | -2.5% |
| Valuation | |||||
| P/B | 1.02 | 1.02 | 2.01 | 1.58 | 1.07 |
| Growth & Yield | |||||
| Revenue Growth | -2.1% | -2.1% | 925.0% | 154.4% | — |
| EPS Growth | 23.3% | 23.3% | 33.1% | -541.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-27.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.03 → -0.79
Residual
-27.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.